Study S000798

A Phase III, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of Survodutide Administered Subcutaneously Compared With Placebo in Patients With Obesity Disease in Japanese

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06176365
Acronym: SYNCHRONIZE™JP
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 274
Start: 2024-01-16
Primary completion: 2025-12-03
Lead sponsor: Boehringer Ingelheim
Conditions: Obesity
Interventions: DRUG:Survodutide; DRUG:Placebo matching survodutide
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Percentage change in body weight from baseline to Week 76 [at baseline, at week 76]
Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76 [at baseline, at week 76]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011503	Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial. Yokote K, Diabetes, obesity & metabolism	2026	Protocol	PMID 42219222 DOI	cites ClinicalTrials.gov:NCT06176365; registry reference DERIVED:42219222